{"organizations": [], "uuid": "54452a82999448cfe539f1145843feaa7bd45a13", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-shire-says-ema-has-validated-its-m/brief-shire-says-ema-has-validated-its-marketing-authorization-application-for-lanadelumab-idUSFWN1RA159", "country": "US", "domain_rank": 408, "title": "BRIEF-Shire ‍says EMA has validated its marketing authorization application for Lanadelumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-29T09:16:00.000+03:00", "replies_count": 0, "uuid": "54452a82999448cfe539f1145843feaa7bd45a13"}, "author": "", "url": "https://www.reuters.com/article/brief-shire-says-ema-has-validated-its-m/brief-shire-says-ema-has-validated-its-marketing-authorization-application-for-lanadelumab-idUSFWN1RA159", "ord_in_thread": 0, "title": "BRIEF-Shire ‍says EMA has validated its marketing authorization application for Lanadelumab", "locations": [], "entities": {"persons": [], "locations": [{"name": "canada", "sentiment": "none"}], "organizations": [{"name": "brief-shire", "sentiment": "negative"}, {"name": "ema", "sentiment": "negative"}, {"name": "lanadelumab reuters staff    shire plc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29, 2018 / 6:16 AM / Updated 5 minutes ago BRIEF-Shire ‍says EMA has validated its marketing authorization application for Lanadelumab Reuters Staff \n  Shire Plc: \n* ‍ANNOUNCED EUROPEAN MEDICINES AGENCY HAS VALIDATED ITS MARKETING AUTHORIZATION APPLICATION FOR LANADELUMAB (SHP643)​ \n* ‍REPORTS THAT HEALTH CANADA HAS COMPLETED SCREENING AND ACCEPTED NEW DRUG SUBMISSION UNDER PRIORITY REVIEW FOR INVESTIGATIONAL COMPOUND​ \n* ‍HEALTH CANADA’S RECENT ACCEPTANCE OF LANADELUMAB NDS FOR PRIORITY REVIEW SHORTENS REVIEW TIMELINE FROM 300 TO 180 DAYS​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-29T09:16:00.000+03:00", "crawled": "2018-03-29T09:24:52.001+03:00", "highlightTitle": ""}